- Home
- MUJ vs MYGN Comparison
MUJ vs MYGN Comparison
Compare MUJ & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MUJ
- MYGN
- Stock Information
- Founded
- MUJ 1998
- MYGN 1991
- Country
- MUJ United States
- MYGN United States
- Employees
- MUJ N/A
- MYGN N/A
- Industry
- MUJ Investment Bankers/Brokers/Service
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- MUJ Finance
- MYGN Health Care
- Exchange
- MUJ Nasdaq
- MYGN Nasdaq
- Market Cap
- MUJ 606.3M
- MYGN 642.0M
- IPO Year
- MUJ N/A
- MYGN 1995
- Fundamental
- Price
- MUJ $11.65
- MYGN $7.58
- Analyst Decision
- MUJ
- MYGN Hold
- Analyst Count
- MUJ 0
- MYGN 13
- Target Price
- MUJ N/A
- MYGN $13.50
- AVG Volume (30 Days)
- MUJ 108.0K
- MYGN 1.5M
- Earning Date
- MUJ 01-01-0001
- MYGN 11-06-2025
- Dividend Yield
- MUJ 4.36%
- MYGN N/A
- EPS Growth
- MUJ N/A
- MYGN N/A
- EPS
- MUJ N/A
- MYGN N/A
- Revenue
- MUJ N/A
- MYGN $832,900,000.00
- Revenue This Year
- MUJ N/A
- MYGN $0.17
- Revenue Next Year
- MUJ N/A
- MYGN $6.19
- P/E Ratio
- MUJ N/A
- MYGN N/A
- Revenue Growth
- MUJ N/A
- MYGN 3.83
- 52 Week Low
- MUJ $9.74
- MYGN $3.76
- 52 Week High
- MUJ $11.70
- MYGN $26.60
- Technical
- Relative Strength Index (RSI)
- MUJ 67.18
- MYGN 55.60
- Support Level
- MUJ $11.51
- MYGN $7.04
- Resistance Level
- MUJ $11.49
- MYGN $8.25
- Average True Range (ATR)
- MUJ 0.12
- MYGN 0.38
- MACD
- MUJ 0.00
- MYGN -0.05
- Stochastic Oscillator
- MUJ 84.21
- MYGN 45.74
About MUJ Blackrock MuniHoldings New Jersey Quality Fund Inc.
BlackRock MuniHoldings New Jersey Quality Fund Inc is a closed-end management investment company. The investment objective of the company is to provide shareholders with current income exempt from U.S. federal income tax and New Jersey personal income taxes. The fund invests in a portfolio of long-term, investment-grade New Jersey municipal obligations.
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.